Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium infantis CCFM111
- Development stage
- Unknown
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium infantis CCFM111 is a specific probiotic strain of the species Bifidobacterium longum subsp. infantis, isolated and characterized for its potential health benefits in humans, particularly infants. This strain is part of the broader group of lactic acid bacteria and is naturally found in the human gastrointestinal tract, especially in breastfed infants[5][7]. It plays a key role in supporting gut health by modulating the gut microbiota, producing short-chain fatty acids (SCFAs), and exerting anti-inflammatory effects[5]. The mechanism of action includes colonization resistance against pathogens through production of antimicrobial substances such as lactic acid and bacteriocins[2][5]. B. infantis strains are well adapted to utilize human milk oligosaccharides (HMOs), which supports their growth and dominance in the infant gut microbiome[3][4]. The specific strain CCFM111 has been studied for its potential to improve immune function, reduce inflammation, and support digestive health.
- Other names
- 婴儿双歧杆菌CCFM111Bifidobacterium longum subsp. infantis CCFM111
Beyond the preview
Go deeper on bifidobacterium infantis CCFM111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium infantis CCFM111.